File this under: “What were they thinking?”
Cipla, which is one of the world’s largest generic drug manufacturers, was recently cited by inspectors from the U.S. Food and Drug Administration for a litany of violations at a plant in India. But one problem stood out: the company failed to properly keep important manufacturing records and, instead had loaded bags paper scraps onto a truck and stored other bags that were earmarked for shredding.
The contents of the bagged documents referred to batches of unspecified medicines and laboratory samples, but were otherwise not disclosed. But this was highlighted as one of seven significant problems in a heavily redacted, 23-page inspection report that was filed after FDA inspectors last month visited the Cipla facility in Madhya, Pradesh, India.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect